Daniel H. L. Lemmers

Daniel H. L. Lemmers

Auto-generated profile, based on publicly available information

Daniel H. L. Lemmers

Amsterdam UMC, Location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
DLDaniel H.L. Lemmers
Daniel H.L. Lemmers
Mohammed Abu HilalMohammed Abu Hilal
Mohammed Abu Hilal
CBClaudio Bnà
Claudio Bnà
CPChiara Prezioso
Chiara Prezioso
ECErika Cavallo
Erika Cavallo
GNGiuseppe Natalini
Giuseppe Natalini
Background: In mechanically ventilated acute respiratory distress syndrome (ARDS) patients infected with the novel coronavirus disease (COVID-19), we frequently recognised the development of pneumomediastinum and/or subcutaneous emphysema despite employing a protective mechanical ventilation strategy. The purpose of this study was to determine if the incidence of pneumomediastinum/subcutaneous emphysema in COVID-19 patients was higher than in ARDS patients without COVID-19 and if this difference could be attributed to barotrauma or to lung frailty.Methods: We identified both a cohort of patients with ARDS and COVID-19 (CoV-ARDS), and a cohort of patients with ARDS from other causes (noCoV-ARDS).Patients with CoV-ARDS were admitted to an intensive care unit (ICU) during the COVID-19 pandemic and had microbiologically confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. NoCoV-ARDS was identified by an ARDS diagnosis in the 5 years before the COVID-19 pandemic period.Results: Pneumomediastinum/subcutaneous emphysema occurred in 23 out of 169 (13.6%) patients with CoV-ARDS and in three out of 163 (1.9%) patients with noCoV-ARDS (p<0.001). Mortality was 56.5% in CoV-ARDS patients with pneumomediastinum/subcutaneous emphysema and 50% in patients without pneumomediastinum (p=0.46).CoV-ARDS patients had a high incidence of pneumomediastinum/subcutaneous emphysema despite the use of low tidal volume (5.9±0.8 mL·kg−1ideal body weight) and low airway pressure (plateau pressure 23±4 cmH2O).Conclusions: We observed a seven-fold increase in pneumomediastinum/subcutaneous emphysema in CoV-ARDS. An increased lung frailty in CoV-ARDS could explain this finding more than barotrauma, which, according to its etymology, refers to high transpulmonary pressure.

6 April 2023 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
BUBas Uijterwijk
Bas Uijterwijk
KWKongyuan Wei
Kongyuan Wei
MKMeidai Kasai
Meidai Kasai
Benedetto IelpoBenedetto Ielpo
Benedetto Ielpo
JHJony van Hilst
Jony van Hilst
RQRenyi Qin
Renyi Qin

23 February 2024 in Cancers
Verified
Journal Article
Open access
PDF file
BUBas Uijterwijk
Bas Uijterwijk
DLDaniël H. Lemmers
Daniël H. Lemmers
GFGiuseppe Kito Fusai
Giuseppe Kito Fusai
BKBas Groot Koerkamp
Bas Groot Koerkamp
SKSharnice Koek
Sharnice Koek
Mohammed Abu HilalMohammed Abu Hilal
Mohammed Abu Hilal
This international multicenter cohort study included 30 centers. Patients with duodenal adenocarcinoma (DAC), intestinal-type (AmpIT) and pancreatobiliary-type (AmpPB) ampullary adenocarcinoma, distal cholangiocarcinoma (dCCA), and pancreatic ductal adenocarcinoma (PDAC) were included. The primary outcome was 30-day or in-hospital mortality, and secondary outcomes were major morbidity (Clavien-Dindo 3b≥), clinically relevant post-operative pancreatic fistula (CR-POPF), and length of hospital stay (LOS). Results: Overall, 3622 patients were included in the study (370 DAC, 811 AmpIT, 895 AmpPB, 1083 dCCA, and 463 PDAC). Mortality rates were comparable between DAC, AmpIT, AmpPB, and dCCA (ranging from 3.7% to 5.9%), while lower for PDAC (1.5%, p = 0.013). Major morbidity rate was the lowest in PDAC (4.4%) and the highest for DAC (19.9%, p < 0.001). The highest rates of CR-POPF were observed in DAC (27.3%), AmpIT (25.5%), and dCCA (27.6%), which were significantly higher compared to AmpPB (18.5%, p = 0.001) and PDAC (8.3%, p < 0.001). The shortest LOS was found in PDAC (11 d vs. 14–15 d, p < 0.001). Discussion: In conclusion, this study shows significant variations in perioperative mortality, post-operative complications, and hospital stay among different periampullary cancers, and between the ampullary subtypes. Further research should assess the biological characteristics and tissue reactions associated with each type of periampullary cancer, including subtypes, in order to improve patient management and personalized treatment.

9 December 2019 in Injury
Verified
Journal Article
Closed access
PDF file
DLDaniel H.L. Lemmers
Daniel H.L. Lemmers
BLBart Lubberts
Bart Lubberts
RSRuben Stavenuiter
Ruben Stavenuiter
DGDaniel Guss
Daniel Guss
AJAnne H. Johnson
Anne H. Johnson
CDChristopher W. DiGiovanni
Christopher W. DiGiovanni

1 January 2020 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
PDF file
Sara CherriSara Cherri
Sara Cherri
DLDaniel H. L. Lemmers
Daniel H. L. Lemmers
SNSilvia Noventa
Silvia Noventa
MHMohammed Abu Hilal
Mohammed Abu Hilal
AZAlberto Zaniboni
Alberto Zaniboni
Recent literature regarding the outcome of cancer patients infected with COVID-19 are not encouraging. Nevertheless, current evidence on the risk and benefits of continuing oncological treatment of cancer patients during the pandemic remains insufficient. We provide our experience in a center with high access for patients with COVID-19-associated pneumonia in Lombardy, Italy. We conducted a retrospective study using a prospectively maintained database of patients admitted to our hospital between 25 February 2020 and 9 April 2020 with a confirmed diagnosis of COVID-19 pneumonia. A total of 53 patients with a history or current oncological disease were included in this study. Sixteen oncological patients (30.2%) died during hospitalization. Multivariable logistic regression analysis found that age (Odds ratio [OR]: 1.17, p = 0.009), diabetes (OR: 15.05, p = 0.028) and active oncological disease (OR 13.60, p = 0.015) were independently associated with in-hospital mortality. The mortality rate of the total number of cancer patients is about twice as high as that of non-oncological patients admitted to our hospital with a diagnosis of COVID-19. The presence of active oncological disease is independently related to mortality as well as age and diabetes. The majority of patients who died were frail. Careful evaluation of the risks and benefits of treatment in frail patients is needed, considering that difficult access to intensive care may have affected the mortality rate.

1 September 2022 in Surgical Oncology
Verified
Journal Article
Open access
EJE.J.M. de Jong
E.J.M. de Jong
DLD.H.L. Lemmers
D.H.L. Lemmers
ACAndrea Benedetti Cacciaguerra
Andrea Benedetti Cacciaguerra
SBS.A.W. Bouwense
S.A.W. Bouwense
SGS.M.E. Geurts
S.M.E. Geurts
JVJudith De Vos-Geelen
Judith De Vos-Geelen
Ampullary adenocarcinoma (AAC) is a rare neoplasm which as a result is lacking specific treatment guidelines. This international survey study was performed to gain insight in the current daily practice of AAC. Surgeons and medical oncologists, whom were members of the Dutch Pancreatic Cancer Group, International Study Group on Ampullary Cancer, International Hepato-Pancreato-Biliary Association, European and International Consortium on Minimally Invasive Pancreatic Surgery, or contributed to (peri)ampullary cancer research, were invited through email and newsletters between January and October 2021. Overall, 217 surgeons and medical oncologists completed the survey. Most of the respondents work in Europe (60%), and in a pancreatic expertise center (86%). The majority of respondents (87%) stated that the histological AAC subtype (e.g. intestinal vs. pancreatobiliary) was determined in the resection specimen. Neoadjuvant treatment for resectable disease was considered by 24% and adjuvant therapy by 90% of the respondents, with 80% of them choosing adjuvant chemotherapy alone. The formation of multidisciplinary teams, improvement in resection procedures, increased availability of chemotherapy regimens, and increased knowledge on tumor biology were considered as the most important developments in the last five years. The necessity for randomized controlled trials was mentioned by 50% of the respondents. This international survey highlights the existing variation in the management of patients with AAC, especially regarding the use of (neo)adjuvant therapy. More data from trials and international registries are needed to develop evidence-based guidelines on surgical and oncological management with the ultimate aim to improve outcomes for patients with AAC.